SARS-CoV-2 recombinant spike protein (Center for Genetic Engineering and Biotechnology)

The SARS-CoV-2 recombinant spike protein is a key component in many COVID-19 vaccines and therapeutics. It is a glycoprotein that mediates viral entry into host cells by binding to the human angiotensin-converting enzyme 2 (ACE2) receptor. As an antigen, it elicits an immune response, leading to the production of neutralizing antibodies and T-cells, thereby preventing or mitigating SARS-CoV-2 infection. Various formulations exist, including nanoparticle vaccines, and some are developed using insect cells or plant-based systems. The "low-dose" aspect refers to a specific concentration used in certain vaccine candidates, such as those studied in clinical trials.

Other names

S proteinSpike glycoproteinRecombinant S-protein vaccineRecombinant prefusion spike protein vaccineRecombinant SARS-CoV-2 S1 Subunit Protein (RBD)NCP-CoV RBDNCP-CoV SpikeNCP-CoV s1NCP-CoV s2RBDS1S-1S 1S2S-2S 2Spike RBDcoronavirus spikecov spikencov RBDncov s1ncov s2ncov spikenovel coronavirus RBDnovel coronavirus s1novel coronavirus s2novel coronavirus spike